T-type calcium channel blockade in the management of chronic ischemic heart disease.
The T-type calcium channel offers a new therapeutic target for treatment of patients with cardiovascular disease. Mibefradil, a T channel blocker, produces heart rate slowing and coronary vasodilatation but without the negative inotropic effect commonly seen when L-type channel blockers are used. The present study shows Mibefradil prevents ischemic episodes that are and are not preceded by an increase in heart rate. Although Mibefradil has been withdrawn because of multiple drug interactions, new T-type calcium channel blockers are under development.
Marsh
J D
JD
Antman
E M
EM
D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D015220:Calcium Channels / Q000187:drug effects; D002908:Chronic Disease; D004347:Drug Interactions; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D020748:Mibefradil / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000517:prevention & control
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D020748:Mibefradil